商业化装机方面，公司旗下各产品共完成商业化装机150余台。其中，图迈全球范围内的商业化装机量 已突破百台，该百台装机均已取得用户签署的装机验收报告。公司称，图迈成为首个实现百台商业化装 机的国产腔镜手术机器人，不仅证明其已具备行业基础设施级的系统可靠性与临床稳定性，也标志着其 在质量合规、生产工艺、工程验证、系统交付、临床适配及全流程保障能力等关键体系上实现了全面跃 升。 在国内市场，图迈在头部公立医院及高端非公立医院市场均取得突破性进展，装机医院中百强医院占比 已达到23%，三甲医院占比超过90%，图迈已逐步形成以临床价值驱动、专业能力沉淀为核心的高质量 装机格局。截至目前，图迈海外市场布局已广泛覆盖亚洲、欧洲、非洲、大洋洲、南美洲的40余个国家 和地区，获得当地顶级机构的认可，并已在15个国家实现"多台销售、多院装机"，实现在全球不同地域 成熟医疗体系内的常态化、网络化、规模化使用。 公司表示，这一里程碑式突破，不仅标志着国产手术机器人在微创与微无创诊疗关键技术路径上实现系 统性全覆盖，也意味着中国在该领域已无关键技术"空白"。在此基础上，一个由微创机器人持续构建， 以体系化创新为内核、以平台化能力输出为 ...

微创机器人-B(02252)早盘涨超6%，截至发稿，涨4.48%，报21港元，成交额4437.75万港元。 值得注意的是，今年10月，摩根大通发布研报表示，微创机器人全球订单动力强劲，截至今年10月8 日，其累计手术机器人订单逾170套，高于8月底的150套。该行基于图迈累计订单约100套，上调微创机 器人今年完成安装数量预测，由84套上调至105套，主要在海外增长及假设订单可在少于一季内转化为 销售入账。更高的安装量基础及产品组合改善，以及预期毛利率1至1.5个百分点改善。 消息面上，香港交易所在12月9日正式发布旗下首支港股科技指数——科技100指数。其中，微创机器人 被纳入科技100指数，充分体现了资本市场对公司在生物科技领域的技术创新实力、行业龙头地位及长 期增长潜力的高度认可与坚定信心。 ...

12月15日，中国证监会国际合作司发布《关于深圳市精锋医疗科技股份有限公司境外发行上市及境内未上市股份"全流通"备案通知书》。精锋医疗拟发行不 超过31,880,500股境外上市普通股并在香港联合交易所上市。该公司49名股东拟将所持合计295,880,748股境内未上市股份转为境外上市股份，并在香港联合 交易所上市流通。 招股书显示，精锋医疗致力于设计、开发及制造手术机器人。精锋多孔腔镜手术机器人MP1000为公司建议核心产品，而精锋单孔腔镜手术机器人SP1000为 关键在研产品。 根据弗若斯特沙利文的资料，公司是中国首家已完成多孔及单孔腔镜手术机器人关键性临床试验的公司。MP1000及SP1000均已具备通过绿色通道进行国家 药监局有关创新医疗（002173）器械的快速审查资格。公司于2022年12月获得国家药监局对MP1000用于泌尿外科手术的注册批准。中国手术机器人市场竞 争激烈。于最后可行日期，公司于中国有五家公司的多孔腔镜手术机器人获批，惟单孔腔镜手术机器人均未获批。 ...

文章来源：MedRobot 转载要求：可以直接转载，请在文首注明来源 MedRobot 《2025手术机器人白皮书》 电子版，今天正式上线了 ！ 2025年9月5 - 6日， MedRobot 在第三届全球手术机器人大会上发布了纸质版。现场不少老师和企业朋友一边翻看、一边给我们提建议，也有很多参会者在离开 前特地叮嘱："电子版出了记得第一时间发给我。"为此 ， 编辑团队 在 过去几个月里又对白皮书做了一轮完整的校对与内容优化，把 当时 没来得及补充的数据和 细节都重新核对了一遍 ， 希望电子版能以更完整的形态呈现给行业读者。现在，它终于准备好了。 这是 MedRobot 连续第三年推出手术机器人白皮书。我们知道，每位阅读它的人，可能都站在不同的角色——做临床的、做工程的、做产品的、做投资的、做战 略的——但大家关心的其实都是同一件事： 手术机器人到底在往哪里走？它真正的价值是什么？未来的路该怎么判断？ 这六个部分，恰好构成未来外科的基本图景： 这本白皮书，也许能给出一部分答案。 获取方式 ： 点击文末"阅读原文" MedRobot 2025 白皮书系列 2025手术机器/ 日 17:55 价值与关 Surgi ...

手术机器人大奖颁奖仪式、白皮书发布、展位、主题演讲—— 如希望合作，请联系思宇工作人员（Alice 微信号 suribot21，Ziana微信号suribot22）等。 MedRobot 第四届全球手术机器人大会（Global Medical Robotics Conference 2026） 将于 2026 年 9 月 10-11 日 在北京中关村展示中心举办。 全球手术机器人大会已连续举办三届，逐渐成为行业默认的年度坐标。企业、医院和工程团队会把这里作 为观察行业节奏、确认技术方向、判断下一阶段重点的参照点。对整个赛道而言，它不仅是信息汇集的场 合，更是一年一次让行业对齐认识、看清走向的窗口。 2026年，大会将围绕" 临床价值 × 工程体系 × 出海路径 × 资本逻辑 "展开，汇集全球企业、临床专家、工 程团队与资本力量，共同梳理行业趋势、验证真实落地，讨论未来十年的技术与产业框架。 # 手术机器人：未来医疗的确定性方向 ——全球投入、赛道分化、中国出海、资本加速的 2026 在所有高端医疗设备中， 手术机器人 是极少数能够同时代表未来临床技术路径、工程系统能力、产业竞争力 与国家装备水平的赛道。 20 ...

Core Viewpoint - In 2024, MicroPort Robotics faced significant challenges due to its own R&D and commercialization struggles, compounded by governance issues at its parent company. However, changes in the parent company's shareholding structure and the potential of its equipment and consumables business model have led to a resurgence in the company's stock performance [1]. Stock Performance - MicroPort Robotics experienced two significant price surges in 2024, with the stock reaching a high of 33.70 HKD, marking a maximum increase of 252.14% [2]. - Following the peak on October 8, the stock price fell to 21.20 HKD by November 21, representing a decline of 37.09% from its high [2]. - Investor sentiment shifted from divergence to consensus, with Hong Kong Stock Connect funds reversing their previous buying and selling strategies to accumulate shares during the downturn [2][8]. Technical Analysis - The stock's price movement in September showed a strong upward trend, with a nearly 40% increase driven by a "three consecutive days of gains" pattern, leading to a significant increase in trading volume [3]. - The Bollinger Bands (BOLL) indicated a breakout from previous trading ranges, with the stock showing a "six consecutive days of gains" pattern, establishing a steep upward channel [3]. - Despite the recent volatility, the distribution of shares remains concentrated at lower price levels, suggesting potential support for future price movements [3]. Volume and Market Sentiment - The stock's price increase was accompanied by declining trading volumes, indicating a lack of buying momentum, which is typically seen as a bearish signal [5]. - As the stock price fell below key technical levels, trading volumes decreased significantly, reflecting a shift in investor sentiment from active selling to cautious observation [7]. Institutional Activity - Recent trading data indicates that Hong Kong Stock Connect funds have begun to accumulate shares, contrasting with their previous selling behavior during the stock's earlier price increases [8][10]. - Over the past 60 days, these funds have been net sellers, but recent trends show a shift towards buying as the stock stabilizes [10]. Financial Performance - MicroPort Robotics reported a total revenue of 176 million HKD for the first half of 2025, a year-on-year increase of 77%, driven by significant growth in overseas markets [13]. - The company has improved its cost management, resulting in a 59% reduction in net losses during the same period [13]. - Following positive financial results, Morgan Stanley has raised its target price for MicroPort Robotics, reflecting confidence in the company's growth potential [14].

Core Insights - The surgical robotics industry is experiencing a surge in collaborations with NVIDIA, with over 8 surgical robotics companies announcing partnerships to integrate NVIDIA's advanced AI and robotics platforms into their systems [1][2] - NVIDIA's IGX Thor platform, featuring 5581 FP4 TFLOPS AI computing power and 400GbE network capabilities, represents a significant leap in computational efficiency and perception capabilities compared to previous platforms [1][9] - Companies like EndoQuest Robotics and CMR Surgical are among the first to adopt the IGX Thor platform, aiming to enhance their robotic systems' performance and capabilities [1][10] Collaboration with NVIDIA - EndoQuest Robotics plans to integrate NVIDIA's IGX Thor platform into its next-generation surgical robot [2] - CMR Surgical has become one of the first global adopters of the IGX Thor platform [2] - Other companies such as Johnson & Johnson, XCath, Asensus, Moon Surgical, Virtual Incision, Neptune Surgical, and Stereotaxis have also formed partnerships with NVIDIA to leverage its technology [1][2] Innovations in Automation and Intelligence - Domestic companies like MicroPort, Precision Medical, and Tianzhihang have already introduced surgical robots equipped with advanced imaging, intelligent navigation, surgical planning, and decision support features [3] - Companies like GeroTech have showcased fully automated surgical solutions, achieving higher levels of automation in surgical procedures [3][4] - The collaboration with NVIDIA is expected to further enhance the capabilities of these robots, particularly in real-time perception and decision-making [12] Computational Power as a Foundation - The demand for computational power in surgical robotics is increasing due to the growing complexity of algorithms and clinical requirements [5] - NVIDIA's solutions are seen as essential for meeting the computational needs for real-time environment perception, data processing, and multi-modal data integration [5][6] - The need for high computational power is critical for pre-operative, intra-operative, and post-operative functionalities [6][7] Competitive Landscape - The partnerships with NVIDIA may enable these surgical robotics companies to compete more effectively with established players like Intuitive Surgical's da Vinci system [9][12] - The IGX Thor platform's capabilities, such as enhanced AI vascular recognition and low-latency control, provide a competitive edge for companies like CMR Surgical [10] - The integration of NVIDIA's platforms is expected to accelerate the development of innovative surgical robots, potentially reshaping the competitive landscape [12][14] Future Directions and Challenges - The surgical robotics industry is moving towards greater automation and intelligence, but challenges such as data availability, regulatory hurdles, and ethical considerations remain [15] - The collaboration with NVIDIA is anticipated to play a crucial role in overcoming these challenges and driving innovation in the field [12][15] - The shift towards software-driven and computationally powered surgical robots is expected to continue, with a focus on enhancing automation and intelligence [14][15]

Core Insights - Shenzhen has 42 unicorn companies in 2024, with a total valuation of $159.9 billion and an average valuation of $3.71 billion, marking a significant increase in unicorn numbers compared to other major cities in China [1][7] - The city has produced 13 new unicorns, accounting for 25% of the national total, making it the leading city in terms of new unicorns [1][7] - Shenzhen's unicorns are primarily concentrated in hard technology sectors, with 66.7% of them focusing on this area, showcasing strong innovation capabilities [3][9] Growth Factors - The rapid growth of unicorns in Shenzhen is attributed to a shift in policy from "single-point support" to "ecological empowerment," creating a comprehensive support system [4][10] - The "20+8" strategic emerging industry cluster policy has been pivotal in supporting sectors like integrated circuits, robotics, and clean energy, aligning with the distribution of unicorns in hard tech [4][10] - Shenzhen aims to cultivate 80 unicorns by 2027 through a multi-dimensional support system encompassing finance, talent, and innovation ecosystems [4][10] Innovation and Patents - Shenzhen unicorns hold an average of 141 authorized invention patents per company, significantly higher than Beijing (74) and Shanghai (81), indicating a robust innovation environment [3][9] - The city has a total of 151 invention applications per company, nearly double that of Beijing and Shanghai [3][9] Global Expansion - Over 80% of Shenzhen's unicorns are global companies, actively expanding into international markets through overseas factories and marketing networks [5][11] - Companies like XREAL and欣旺达动力 are seizing opportunities in the global market, with XREAL's AR device achieving significant overseas revenue [6][11] - The establishment of cross-border research environments and support for overseas technology acquisitions are facilitating this global expansion [6][11]

Core Insights - Cornerstone Robotics, a Chinese innovative surgical robot company, has successfully completed a new funding round of approximately $200 million, exceeding its target [3][4]. Funding Details - The funding round received investments from Hong Kong Investment Management Company, a global strategic investor, and a top sovereign wealth fund, along with continued support from investors like Qiming Venture Partners, Daohe Investment, Gao Rong Capital, and Xianfeng [4][9]. - The raised funds will primarily be used to accelerate commercialization in China and overseas, as well as to promote the research and clinical registration of next-generation products [5]. Strategic Importance of Investors - The investment from Hong Kong Investment Management Company is significant as it represents a government-backed entity that supports innovative enterprises with a global vision, reflecting confidence in Cornerstone Robotics' product innovation and commercialization capabilities [7][9]. - The involvement of a global strategic investor and a top sovereign fund is expected to enhance Cornerstone Robotics' global market expansion and facilitate product market access and regional cooperation [9]. Company Overview - Since its establishment in 2019, Cornerstone Robotics has become a unicorn in the field of innovative surgical robots, driven by its vision of leading medical innovation and enhancing global health [9]. - The company's core product, the Sentire® laparoscopic surgical robot, has received approval from the National Medical Products Administration (NMPA) in China and is being used in clinical applications across top hospitals in mainland China, Hong Kong, and Europe [9]. Future Outlook - The CEO of Cornerstone Robotics emphasized that 2025 will be a significant milestone for the company, highlighting the importance of government support in driving technological innovation and global expansion [10]. - The Hong Kong Investment Management Company's CEO noted that Cornerstone Robotics embodies the spirit of innovation in Hong Kong's medical robotics sector and aligns with their standards of accessibility, applicability, and affordability [11].

Core Insights - The recent surge in interest and investment in surgical robots, highlighted by Conostent's $200 million funding round, indicates a growing market for these technologies in healthcare [2][10] - Conostent's Sentire system is positioned as a mid-priced alternative to the dominant Da Vinci system, aiming to increase accessibility and adoption in hospitals [6][7] Company Overview - Conostent was founded in 2019 by Guowei Ou, who has a background in mechanical engineering and experience with Intuitive Surgical [2][5] - The Sentire system allows for minimally invasive surgeries using a joystick-controlled robotic arm, providing enhanced precision and 3D visualization for surgeons [4][6] Market Dynamics - There have been 31 funding events for surgical robots in China this year, indicating a robust investment landscape [2] - The current penetration of surgical robots in Chinese hospitals is low, with only about 380 Da Vinci systems installed across 300 hospitals, compared to approximately 37,000 hospitals in total [11][12] Competitive Landscape - The Sentire system is expected to be priced at 40-60% of the Da Vinci system, making it a more affordable option for hospitals [6][7] - The market for domestic surgical robots is projected to grow significantly, with penetration in county-level hospitals expected to rise from 6.5% in 2023 to 25% by 2030 [15][16] Future Outlook - The surgical robot market is still in its early application stages, presenting a timely opportunity for investment and growth [10][15] - Conostent anticipates approximately 34.23 million new opportunities for minimally invasive surgeries in China by 2030, indicating a substantial market potential [16]